Skip to main content
4SC AG logo

4SC AG — Investor Relations & Filings

Ticker · VSC ISIN · DE000A3E5C40 LEI · 391200QOKN7LGVP0RQ86 F Manufacturing
Open in API
Filings indexed 719 across all filing types
Latest filing 2011-11-07 Earnings Release
Country DE Germany
Listing F VSC

About 4SC AG

https://www.4sc.com/

4SC AG is a biopharmaceutical company that formerly focused on the research and development of small-molecule drugs for cancer treatment. The company's strategy centered on addressing diseases with high unmet medical needs by developing innovative therapies that targeted epigenetic mechanisms of action. According to the company's official statements, it currently has no products under development and no operational business.

Recent filings

Filing Released Lang Actions
4SC presents encouraging final results of Vidofludimus Phase IIb COMPONENT study in Rheumatoid Arthritis at ACR Meeting in Chicago
Earnings Release Classification · 99% confidence The document is a press release dated November 7, 2011, announcing the presentation of final results from a Phase IIb clinical study (COMPONENT study) for the drug Vidofludimus at the ACR Meeting. It details clinical outcomes, safety profiles, and future development plans. This type of announcement, which communicates key business/research updates outside of mandatory periodic financial filings (like 10-K or IR), is best classified as a general Regulatory Filing or Corporate News announcement, as it doesn't fit the specific definitions for Earnings Release (ER), Interim Report (IR), or Investor Presentation (IP). Since it is a corporate news item disseminated via DGAP (a regulatory announcement service) and doesn't fit a more specific category like LTR (Legal) or CAP (Financing), the most appropriate fallback is Regulatory Filings (RNS). FY 2011
2011-11-07 English
4SC to Host Conference Call on 8 November, 2011 to Present Q3 and first Nine Months 2011 Financial Results
Regulatory Filings Classification · 99% confidence The document is a short announcement dated November 2, 2011, stating that 4SC AG will announce its financial results for Q3 and the first nine months of 2011 on November 8, 2011, and will host a conference call to present these results. This is not the actual financial report (IR or ER), nor is it the transcript of the call (CT). It is an announcement about an upcoming event where financial results will be discussed. This fits the definition of an Earnings Release (ER) announcement, which is the initial announcement of periodical financial results, or potentially a Report Publication Announcement (RPA) if it were announcing the release of the report itself. Since the core purpose is to announce the *presentation* of the Q3 results via a conference call, it is most closely aligned with an Earnings Release announcement, even though the full results document might follow later. Given the options, ER is the best fit for an announcement preceding the detailed results presentation.
2011-11-02 English
4SC's anti-cancer compound Resminostat receives positive opinion for orphan medicinal product designation in Europe to treat Hodgkin's Lymphoma
Environmental & Social Information Classification · 99% confidence The document is a press release dated October 13, 2011, announcing that 4SC AG's anti-cancer compound, Resminostat, received a positive opinion from the European Medicines Agency (EMA) for orphan medicinal product designation for treating Hodgkin's Lymphoma. This type of announcement, detailing clinical/regulatory progress and business updates outside of mandatory periodic financial reports (like 10-K or IR), typically falls under general corporate news or regulatory updates. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific transaction notice (DIV, CAP, DIRS), it best fits the general 'Regulatory Filings' (RNS) category, which serves as a broad category for miscellaneous corporate announcements not covered by more specific codes. It is not an announcement of a report publication (RPA) because it contains substantive news content, not just a notice that a report is available.
2011-10-13 English
4SC's Resminostat receives FDA Orphan Drug Status for Hodgkin's Lymphoma
Regulatory Filings Classification · 100% confidence The document is a press release dated September 26, 2011, announcing that 4SC's compound, Resminostat, received Orphan Drug Status from the FDA for Hodgkin's Lymphoma. It discusses clinical trial results (Phase II SAPHIRE study) and future development plans. This type of announcement, detailing a specific regulatory event (FDA designation) and key clinical/business updates, is typically classified as a general corporate news release or regulatory filing that doesn't fit the more specific financial report categories (like 10-K, ER, or IR). Since it is a specific, non-financial regulatory/business update that doesn't fit other categories (like DIRS, DIV, CAP, etc.), the most appropriate fallback is Regulatory Filings (RNS), as it is a formal announcement disseminated via a service like DGAP.
2011-09-26 English
4SC to Present at the Jefferies 2011 Global Healthcare Conference in London
Regulatory Filings Classification · 100% confidence The document is a short news release dated September 21, 2011, announcing that the CEO of 4SC AG will present at the Jefferies 2011 Global Healthcare Conference. It contains company background information and contact details, but it is not a comprehensive financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing detailing specific transactions or results. Since it is a general corporate announcement about participation in an external industry event, and it doesn't fit the specific categories like AGM-R, ER, or DIV, it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous corporate news disseminated via services like DGAP.
2011-09-21 English
4SC's Resminostat Meets Primary Efficacy Endpoint in Phase II Trial in Hodgkin's Lymphoma (HL)
Earnings Release Classification · 99% confidence The document is a press release dated September 6, 2011, announcing positive topline data from a Phase II clinical trial (SAPHIRE trial) for the drug resminostat in Hodgkin's Lymphoma. It details efficacy endpoints, safety profiles, and mentions future plans to discuss registration with regulatory agencies. It also announces a conference call to discuss these results. This content is characteristic of an initial announcement of periodic financial/operational results, focusing on key performance indicators (clinical trial success in this case, which drives future revenue/value). This aligns best with the 'Earnings Release' (ER) definition, as it is the initial release of key performance data for a period/trial, even though it is not strictly quarterly financial earnings. Since it is a corporate news release announcing a major operational milestone (clinical trial success) and includes details about an upcoming conference call, it functions similarly to an ER. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or just a simple announcement of a report publication (RPA). Q3 2011
2011-09-06 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.